Exelixis, Inc. (EXEL) stock price, chart and research
Exelixis, Inc. (EXEL) last traded at $71.74 at the close on November 9, 2026, up $2.17 (3.12%) on the day.
- Day range: $69.39 to $72.15
- 52-week range: $39.71 to $73.69
- Market cap: $17.51 billion
- P/E (trailing 12 months): 21.48
- Forward P/E: 16.78
- EPS (trailing 12 months): $3.34
- Dividend yield: 0.00%
- Volume: 4,826,132 shares
About Exelixis, Inc.
Sector: Healthcare; industry: Biotechnology; headquarters: United States; CEO: Dr. Michael M. Morrissey Ph.D.; 1,077 employees; listed since 2000-04-17.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a…
Financials
Revenue over the last 12 months was $2.50 billion, net income $885.1 million, a profit margin of 35.4%. Revenue grew 9.1% from a year earlier.
Institutional owners of EXEL (13F)
Tracked managers holding EXEL in 13F filings for the quarter ending 2026-09-30:
- Dimensional Fund Advisors LP: $224.4 million, 0.04% of its portfolio (reduced)
- Simplex Trading, LLC: $233,000.00, 0.01% of its portfolio (reduced)
ETFs that hold EXEL
Research EXEL with LunaTerminal
- Interactive chart from one day to ten years, with volume, technicals and comparisons.
- Valuation, analyst ratings, dividends, earnings history and recent news.
- Ask LunaTerminal about EXEL: AI answers that cite dated data; no account needed for 5 prompts
- 13F filings: which managers own what
- How advisors use LunaTerminal for market research
Market data via Fear & Greed (feargreedflow.com); 13F holdings from SEC filings. Market data can be delayed; check dates before relying on a figure. Answers are research, not financial advice.